The board of directors of Shanghai Henlius Biotech, Inc. announced that, recently, the supplementary application of HLX03 (adalimumab injection) for the new indication of uveitis, independently developed by the Company has been accepted by the Center for Drug Evaluation of the National Medical Products Administration. HLX03 (adalimumab injection) is a monoclonal antibody biosimilar independently developed by the Company in accordance with the guiding principle on biosimilar in China and was approved for commercialisation in Mainland China (excluding Hong Kong, Macao and Taiwan regions, similarly hereinafter) in December 2020 to be used for the approved indications: rheumatoid arthritis; ankylosing spondylitis; psoriasis. This application is to include the indication of uveitis, which the original drug Humira® (adalimumab injection) has been approved for commercialisation in Mainland China. The indication is expanded mainly based on the proven similarity between HLX03 (adalimumab injection) and Humira®. With same action mechanism, and selection of sensitive patient population and appropriate indications for the key clinical trials, sufficient safety and immunogenicity data, the indication is expanded in compliance with the requirements of the Technical Guidelines for R&D and Evaluation of Biosimilars (Trial) and Clinical Trial Guidelines for Adalimumab Injection Biosimilars and other regulations and policies in China.